The leukotrienes, a family of highly potent biological substances derived from arachidonic acid, are suggested to play an important role in the development of tissue inflammation.1 Leukotriene B4 (LTB4) is a major player whose synthesis is mainly controlled by 5-lipoxygenase. Among several diseases, hyperkeratotic inflammatory skin diseases and especially psoriasis seem to respond to LTB4 inhibitors.2 Recent study findings indicate the potential involvement of the arachidonic acid pathway in the development of inflammation in acne and provide logical support for the use of LTB4 inhibitors in acne treatment.3
Zouboulis CC, Nestoris S, Adler YD, et al. A New Concept for Acne Therapy: A Pilot Study With Zileuton, an Oral 5-Lipoxygenase Inhibitor. Arch Dermatol. 2003;139(5):668–670. doi:10.1001/archderm.139.5.668
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: